The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes. Nephrologists focus on renal preservation, while ...

The US FDA has imposed a clinical hold on Kezar Life Sciences’ IND application for zetomipzomib, aimed at treating lupus ...

In the past decade significant contributions have been made to the understanding of acute glomerulonephritis by virtue of advances in many fields, including epidemiology, immunology ...

Kezar Life Sciences said it voluntarily suspended enrollment and dosing in a clinical trial of a treatment for an autoimmune ... to treat patients with lupus nephritis. The review included an ...

Meanwhile, Aurinia reported improved outcomes in lupus nephritis therapy during the European Alliance of Associations for Rheumatology (EULAR) 2024, showing that a treatment regimen including ...

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for ...

Lupus nephritis is a potentially life-threatening ... Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized ... and European ...

The FDA's decision comes after the company said it had paused the mid-stage trial of the drug, zetomipzomib, to review safety ...

10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious ...

About Lupus Nephritis Lupus nephritis ... Monitor for neurologic symptoms. Hyperkalemia: Hyperkalemia, which may be serious and require treatment, has been reported with CNIs, including LUPKYNIS.